Pulse Biosciences CS (PLSE)

$17.91 -1.36 (-7.06%)
Market Cap 1.30B
Revenue (ttm) 0.00
Net Income (ttm) -53.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 189,600
Avg Vol 190,328
Day's Range N/A - N/A
Shares Out 67.27M
Stochastic %K 57%
Beta 1.87
Analysts Strong Buy
Price Target $5.00

Latest News on PLSE

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 25, 2025, 4:05 PM EDT - 1 day ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 24, 2025, 4:05 PM EDT - 2 days ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 3 days ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:46 PM EDT - 4 weeks ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 27, 2025, 4:05 PM EDT - 4 weeks ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 26, 2025, 4:05 PM EDT - 4 weeks ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Mar 7, 2025, 8:00 AM EST - 7 weeks ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 2 months ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Feb 4, 2025, 8:00 AM EST - 2 months ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 30, 2025, 8:00 AM EST - 3 months ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 21, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 3 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 10, 2025, 8:00 AM EST - 3 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 9:00 AM EST - 4 months ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 23, 2024, 4:30 PM EST - 4 months ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 19, 2024, 8:00 AM EST - 4 months ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Dec 17, 2024, 8:00 AM EST - 4 months ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 31, 2024, 2:25 PM EDT - 6 months ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 9:42 PM EDT - 6 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:05 PM EDT - 6 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 30, 2024, 4:02 PM EDT - 6 months ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 6 months ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:50 PM EDT - 9 months ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 9 months ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 12, 2024, 4:01 PM EDT - 9 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Aug 8, 2024, 8:00 AM EDT - 9 months ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Aug 1, 2024, 4:05 PM EDT - 9 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Jul 29, 2024, 4:05 PM EDT - 9 months ago

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Jul 8, 2024, 8:00 AM EDT - 10 months ago

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Jul 3, 2024, 2:44 PM EDT - 10 months ago

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Jun 28, 2024, 8:00 AM EDT - 10 months ago

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Jun 4, 2024, 8:00 AM EDT - 11 months ago

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

May 20, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

May 16, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences Enhances Executive Leadership Team

May 14, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Enhances Executive Leadership Team

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:29 PM EDT - 1 year ago

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

May 9, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

May 2, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:52 PM EDT - 1 year ago

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Mar 28, 2024, 4:12 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Mar 28, 2024, 4:10 PM EDT - 1 year ago

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Mar 8, 2024, 1:17 PM EST - 1 year ago

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Feb 14, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Jan 31, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Jan 2, 2024, 8:00 AM EST - 1 year ago

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Dec 20, 2023, 8:00 AM EST - 1 year ago

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter